We aimed to investigate whether asprosin and PYY could be biomarkers that could identify the disease or phases of the disease, as well as whether the data obtained were related to clinical appearance using PANNS scores, a scale that measures the positive symptoms, negative symptoms, and general psychopathology levels in schizophrenia patients. This evidence concerns the gene PYY and schizophrenia.